XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Schedule of Assumptions Used to Calculate Fair Value of Stock Options

Risk-free interest rates   2.72%
Expected term (in years)   2.6 
Volatility   95.0%
Grant date fair value of awards granted during the period  $22.60 
Summary of Stock Option Activity

A summary of Oncocyte’s 2018 Incentive Plan activity and related information follows (in thousands except weighted average exercise price):

 

   Shares   Number   Number   Weighted 
   Available   of Options   of RSUs   Average 
   for Grant   Outstanding   Outstanding   Exercise Price 
                 
Balance at December 31, 2022   442    428    22   $59.23 
RSUs vested   -    -    (11)  $- 
RSUs granted   (10)   -    5   $- 
Options granted   (178)   178    -   $7.72 
Options forfeited/cancelled   150    (150)   -   $- 
RSUs forfeited/cancelled   2    -    (1)  $- 
Performance RSUs forfeited/cancelled   15    -    (8)  $- 
Balance at June 30, 2023   421    456    7   $38.33 
Options exercisable at June 30, 2023        199        $89.54 
Summary of Stock-based Compensation Expense

Oncocyte recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2023 and 2022 (unaudited and in thousands):

 

 

   2023   2022   2023   2022 
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
Cost of revenues  $2   $-   $12   $- 
Research and development   309    201    632    381 
Sales and marketing   62    -    139    29 
General and administrative   461    1,283    867    2,463 
Discontinuing operations   -    748    18    1,369 
Total stock-based compensation expense  $834   $2,232   $1,668   $4,242 
Schedule of Assumptions Used to Calculate Fair Value of Stock Options

The assumptions that were used to calculate the grant date fair value of Oncocyte’s employee and non-employee stock option grants for the six months ended June 30, 2023 and 2022 were as follows:

 

 

   Six Months Ended 
   June 30, 
   2023   2022 
Expected life (in years)   6.25    6.01 
Risk-free interest rates   3.76%   2.24%
Volatility   105.99%   106.98%
Dividend yield   0%   0%
2010 Plan Activity [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Summary of Stock Option Activity

A summary of Oncocyte’s 2010 Plan activity and related information follows (in thousands except weighted average exercise price):

 

   Shares   Number   Weighted 
   Available   of Options   Average 
Options  for Grant   Outstanding   Exercise Price 
             
Balance at December 31, 2022   -    30   $80.78 
Options exercised   -    -   $- 
Options forfeited, cancelled and expired   -    (1)  $- 
Balance at June 30, 2023   -    29   $80.58 
Exercisable at June 30, 2023        29   $80.58